SCHEMBL15345154

SCHEMBL15345154

Cc1ccc2nn(C3COC3)cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 1/20 0.36
ALDH1A1 P00352 2/20 0.34
NCK1 P16333 1/20 0.34
BACE1 P56817 1/20 0.34
PIM1 P11309 1/20 0.34
OPRK1 P41145 1/20 0.34
IRAK4 Q9NWZ3 4/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
NQO2 P16083 1/20 0.33
LMNA P02545 1/20 0.33
PDE2A O00408 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
MEN1 O00255 1/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27004837 0.88 IRAK4 (0.43) TLR8OPRK1IRAK4
SCHEMBL20117046 0.88 CYP1A2 (0.37) KDM4ECYP1A2ALDH1A1PIM1IRAK4
SCHEMBL27004828 0.85 IRAK4 (0.44) TLR8OPRK1IRAK4
SCHEMBL15345071 0.83 TLR8 (0.40) TLR8PIM1IRAK4
SCHEMBL29141445 0.81 TLR8 (0.36) TLR8IRAK4
SCHEMBL21810482 0.81 TLR8 (0.36) TLR8ALDH1A1BACE1IRAK4NPC1
SCHEMBL15341842 0.81 ALDH1A1 (0.38) TLR8ALDH1A1IRAK4NPC1RAB9A
SCHEMBL27004838 0.80 TLR8 (0.38) TLR8KDM4ECYP1A2ALDH1A1NCK1
SCHEMBL20134852 0.79 TLR8 (0.60) TLR8IRAK4
Hydrochloric Acid SCHEMBL28215651 0.78 TLR8 (0.59) TLR8IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4306520-A1 THIOPHENE COMPOUND AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2024-01-17 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 TLR8 2377/4885KDM4E 4221/4885CYP1A2 807/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 TLR8 2377/4885KDM4E 4221/4885CYP1A2 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.